|
Variable
|
TIF1γ low
|
TIF1γ high
|
Pa
|
TGFβ1 low
|
TGFβ1 high
|
Pa
|
SMAD4 low
|
SMAD4 high
|
Pa
|
|---|
|
No. (%)
|
No. (%)
| |
No. (%)
|
No. (%)
| |
No. (%)
|
No. (%)
|
|---|
|
143 (64.1)
|
80 (35.9)
| |
142 (69.6)
|
62 (30.4)
| |
70 (40.5)
|
103 (59.5)
|
|---|
|
Age (Yr)
|
-Mean (± SD)
|
59.4(±12)
|
55.9(±13)
|
0.048b
|
57.6(±12)
|
59.3(±14)
|
0.37b
|
56.5(±12)
|
57.1 (±12)
|
0.74b
|
|
Age groups
|
- ≤50y
|
37 (26)
|
35 (44)
|
0.006
|
44 (31)
|
21 (34)
|
0.68
|
22 (31)
|
38 (37)
|
0.46
|
|
- >50y
|
106 (74)
|
45 (56)
|
98 (69)
|
41 (66)
|
48 (69)
|
65 (63)
|
|
Side
|
-Right
|
68 (48)
|
37 (46)
|
0.85
|
62 (44)
|
28 (45)
|
0.84
|
30 (43)
|
51 (49)
|
0.39
|
|
-Left
|
75 (52)
|
43 (54)
|
80 (56)
|
34 (55)
|
40 (57)
|
52 (51)
|
|
T. size
|
- ≤2 cm
|
80 (56)
|
35 (44)
|
0.08
|
73 (51)
|
30 (48)
|
0.69
|
31 (44)
|
51 (49)
|
0.49
|
|
- >2 cm
|
63 (44)
|
45 (56)
|
69 (49)
|
32 (52)
|
39 (56)
|
52 (51)
|
|
LN met
|
-Negative
|
85 (59)
|
41 (51)
|
0.24
|
79 (56)
|
35 (57)
|
0.91
|
36 (51)
|
55 (53)
|
0.79
|
|
-Positive
|
58 (41)
|
39 (49)
|
63 (44)
|
27 (44)
|
34 (49)
|
48 (47)
|
|
SBR grade
|
-Gr 1
|
39 (27)
|
6 (7)
|
<0.001
|
30 (21)
|
11 (18)
|
0.82
|
5 (7)
|
26 (25)
|
0.004
|
|
-Gr 2
|
72 (50)
|
30 (38)
|
63 (44)
|
30 (48)
|
35 (50)
|
50 (49)
|
|
-Gr 3
|
32 (23)
|
44 (55)
|
49 (35)
|
21 (34)
|
30 (43)
|
27 (26)
|
|
ER status
|
-Negative
|
13 (9)
|
15 (19)
|
0.035
|
24 (17)
|
6 (10)
|
0.17
|
13 (19)
|
7 (7)
|
0.02
|
|
-Positive
|
129 (91)
|
64 (81)
|
116 (83)
|
56 (90)
|
56 (81)
|
95 (93)
|
|
PR status
|
-Negative
|
28 (20)
|
22 (28)
|
0.18
|
38 (27)
|
11 (18)
|
0.14
|
18 (26)
|
21 (21)
|
0.40
|
|
-Positive
|
113 (80)
|
57 (72)
|
101 (73)
|
51 (82)
|
51 (74)
|
81 (79)
|
|
Her 2 status
|
-Negative
|
126 (91)
|
69 (87)
|
0.35
|
125 (91)
|
54 (89)
|
0.66
|
60 (90)
|
90 (89)
|
0.93
|
|
-Over-expressed
|
12 (9)
|
10 (13)
|
13 (9)
|
7 (11)
|
7 (10)
|
11 (11)
|
|
Breast cancer subtype
|
-Luminal
|
127 (91)
|
64 (81)
|
0.12c
|
114 (83)
|
55 (90)
|
0.31c
|
54 (81)
|
94 (93)
|
0.05c
|
|
-Her2 rich
|
2 (1)
|
3 (4)
|
4 (3)
|
2 (3)
|
2 (3)
|
1 (1)
|
|
-Basal
|
11 (8)
|
12 (15)
|
20 (14)
|
4 (7)
|
11 (16)
|
6 (6)
|
|
(Neo)/ Adjuv. Hormonal ttt
|
-Tamoxifen
|
101 (89)
|
54 (87)
|
0.89c
|
95 (92)
|
44 (83)
|
0.20c
|
48 (89)
|
75 (94)
|
0.48c
|
|
-AI
|
4 (4)
|
3 (5)
|
3 (3)
|
2 (4)
|
1 (2)
|
1 (1)
|
|
-Tamoxifen + AI
|
8 (7)
|
5 (8)
|
5 (5)
|
7 (13)
|
5 (9)
|
4 (5)
|
|
(Neo)/ Adjuv. chemotherapy
|
-Anthra.
|
52 (85)
|
40 (82)
|
0.61
|
58 (76)
|
25 (83)
|
0.59
|
34 (74)
|
44 (80)
|
0.48c
|
|
only
|
9 (15)
|
9 (18)
| |
16 (21)
|
5 (17)
|
c
|
11 (24)
|
11 (20)
|
|
-Anthra. +
| | | | | | |
1 (2)
|
0 (0)
|
|
Taxane
|
0 (0)
|
0 (0)
| |
2 (3)
|
0 (0)
| | | |
|
-Others
| | | | | | | | |
- aCorrelations tested by Pearson’s Chi square test (2sided) unless otherwise specified
- b Difference between means by Student’s T test
- c Fisher’s exact test
